CORONA Remedies
NSE: CORONA · ISIN INE02ZQ01018 · Healthcare
₹2,594.90+60.70 (+2.40%)
Monday 9 November, 12:19 IST. Delayed. Source: Yahoo Finance.
Price chart
₹2,594.90 +60.70 (+2.40%) today
The day
- Previous close
- ₹2,534.20
- Open
- ₹2,524.50
- Day high
- ₹2,719.30
- Day low
- ₹2,500.30
Listed on NSE since 15 December 2025.
Key numbers
- P/E (trailing)
- 79.57
- EPS (trailing)
- ₹32.61
- Price to book
- 19.71
- Dividend yield
- 0.39%
- Return on equity
- 28.3%
- Debt to equity
- 0.14
- Profit margin
- 13.3%
- Volume today
- 1.17 L
- Average volume
- 42,249
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹883.53 Cr | ₹84.93 Cr |
| FY24 | ₹1,013.68 Cr | ₹90.50 Cr |
| FY25 | ₹1,195.51 Cr | ₹149.43 Cr |
| FY26 | ₹1,401.48 Cr | ₹185.12 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹441 Cr | ₹60 Cr | +15.3% |
| Q1 FY27Apr–Jun 2026 | ₹422 Cr | ₹60 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹353 Cr | ₹45 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹342 Cr | ₹41 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹361 Cr | ₹52 Cr | – |
Source: CORONA Remedies’s results filed with NSE, consolidated (the whole group). Net profit is the share of CORONA Remedies’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹447 Cr | ₹434 Cr |
| Investments | ₹16.00 L | ₹17.00 L |
| Inventories | ₹171 Cr | ₹125 Cr |
| Owed by customers | ₹171 Cr | ₹146 Cr |
| Cash and equivalents | ₹2 Cr | ₹2 Cr |
| Total assets | ₹1,247 Cr | ₹1,205 Cr |
| Borrowings | ₹95 Cr | ₹143 Cr |
| Total liabilities | ₹442 Cr | ₹458 Cr |
| Shareholders’ equity | ₹805 Cr | ₹747 Cr |
Source: CORONA Remedies’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About CORONA Remedies
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
- Industry
- Drug Manufacturers - General
- Based in
- Ahmedabad
- Employees
- 5,153
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name CORONA Remedies in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 10 Per Share
Dividend · ex-date 19 June 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.